First Tracks Biotherapeutics Inc(TRAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 15.02% | Shs Outstand | 35.4M | Perf Week | -3.34% |
| Market Cap | 1.45B | Forward P/E | - | EPS next Y | 10.37% | Insider Trans | - | Shs Float | 30.4M | Perf Month | -10.7% |
| Enterprise Value | 1.28B | PEG | - | EPS next Q | -0.9 | Inst Own | 85.64% | Short Float | 12.82% | Perf Quarter | 143.73% |
| Income | - | P/S | - | EPS this Y | 25.56% | Inst Trans | 299.68% | Short Ratio | 5.05 | Perf Half Y | - |
| Sales | - | P/B | 8.48 | EPS next 5Y | 11.2% | ROA | - | Short Interest | 3.89M | Perf YTD | 102.3% |
| Book/sh | 4.77 | P/C | 8.6 | EPS past 3/5Y | - | ROE | - | 52W High | -18.94% ($49.91) | Perf Year | - |
| Cash/sh | 4.7 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 174.86% ($14.72) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 6.92% 6.66% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.28 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 46.4 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.28 | Sales Q/Q | - | SMA20 | -7.76% ($43.86) | Beta | - | Target Price | $69.44 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/12 | SMA50 | 5.99% ($38.17) | Rel Volume | 0.59 | Prev Close | $42.51 |
| Employees | - | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -18.37% - | SMA200 | 44.96% ($27.91) | Avg Volume(3M) | 0.77M | Price | $40.46 |
| IPO | 2026/4/6 | Option/Short | Yes/Yes | Trades | 7407 | Volume | 456,235 | Change | -4.82% |
Company
TRAX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
� This is a clinical-stage biotech company developing antibody therapeutics that modulate immune pathways involved in autoimmune and inflammatory diseases. Its pipeline is centered on immune-modulating antibodies targeting celiac disease and eosinophilic esophagitis, along with a T-cell-targeting antibody aimed at rheumatoid arthritis, and the company is valued based on clinical progress rather than product revenue.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
TRAX makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.6% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 85.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
CANC 0.01%
BBC 0.00%
SGRW 0.00%
HELX 0.00%
XBI 0.00%It ranks #4 in the industry
Based on market cap of $1B.
TRAX $1B PER -
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is TRAX?
TRAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TRAX?
The market cap of TRAX is approximately $1.4B, ranking 2,382 within its sector.
What is the 52-week high and low for TRAX?
TRAX has recorded a 52-week high of $49.91 and a low of $14.72.
